Baroreceptor Reflex in Elderly Essential Hypertensives: Effect of Chronic Inhibition of Angiotensin Converting Enzyme

References

• Gribbin B, Pickering T G, Sleight P, Peto R. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971; 29: 424–429
   PubMed Web of Science ®Google Scholar
• Shimada K, Kitazumi T, Sadakane N, Ogura H, Ozawa T. Age related changes of baroreflex function, plasma norepinephrine, and blood pressure. Hypertension 1985; 7: 113–117
   PubMed Web of Science ®Google Scholar
• Guo G B, Abboud F M. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol 1984; 246: H80–H89
   PubMed Web of Science ®Google Scholar
• Fukiyama K. Central modulation of baroreceptor reflex by angiotensin. Jpn Heart J 1973; 14: 135–139
   PubMedGoogle Scholar
• Ebert T J. Captopril potentiates chronotropic baroreflex responses to carotid stimuli in humans. Hypertension 1985; 7: 602–606
   PubMed Web of Science ®Google Scholar
• Mancia G, Parati G, Pomidossi G, Grassi G, Bortinieri G, Buccino N, Ferrari A, Gregorini L, Rupoli L, Zanchetti A. Modification of arterial barorefiexes by captopril in essential hypertension. Am J Cardiol 1982; 49: 1415–1419
   PubMed Web of Science ®Google Scholar
• Clementi W A, Durst N L, McNay J L, Keeton T K. Captopril modifies the hemodynamic and neuroendocrine response to sodium nitroprusside in hypertensive patients. Hypertension 1986; 8: 229–237
   PubMed Web of Science ®Google Scholar
• Garner M G, Phippard A F, Fletcher P J, Maclean J M, Duggin F F, Horvath J S, Tiller D J. Effect of angiotensin II on baroreceptor reflex control of heart rate in conscious baboons. Hypertension 1987; 10: 628–634
   PubMed Web of Science ®Google Scholar
• Guthrie J P, Jr, Genest J, Nowaczynski W, Boucher R, Kuchel O. Dissociation of plasma renin activity and aldosteronism in essential hypertension. J Clin Endocrinol Metab 1976; 43: 446–448
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ishida H, Nakahashi Y, Nishitani T, Hosoda S, Yokoyama T, Tanaka S, Iimura O. A very sensitive direct radioimmunoassay system for plasma angiotensin II and its clinical application in various hypertensive disease. Jpn Circ J 1984; 48: 1228–1235
   PubMedGoogle Scholar
• Lieberman J. Elevation of serum angiotensin-converting enzyme (ACE) level in sarcoidosis. Am J Med 1975; 59: 365–372
   PubMed Web of Science ®Google Scholar
• Grossman S H, Daveis D, Gunnells C, Shand D G. Plasma norepinephrine in the evaluation of baroreceptor function in humans. Hypertension 1982; 4: 566–571
   PubMed Web of Science ®Google Scholar
• Wallin B G, Sundloef G, Eriksson B-M, Dominiak P, Grobecker H, Lindblad L E. Plasma noradrenaline correlates to sympathetic muscle nerve activity in normotensive man. Acta Physiol Scand 1981; 111: 69–73
   PubMedGoogle Scholar
• Morrow L A, Linares O A, Hill T J, Sanfield J A, Supiano M A, Rosen S G, Halter J B. Age difference in the plasma clearance mechanisms for epinephrine and norepinephrine in humans. J Clin Endocrinol Metab 1987; 65: 508–511
   PubMed Web of Science ®Google Scholar
• Young J B, Rowe J W, Pallotta J A, Sparrow D, Landsberg L. Enhanced plasma norepinephrine response to upright posture and oral glucose administration in elderly human subjects. Metabolism 1980; 20: 532–539
   Google Scholar
• Rubin P C, Scott P JW, McLean K, Reid J L. Noradrenaline release and clearance in relation to age and blood pressure in man. Eur J Clin Invest 1982; 12: 121–125
   PubMed Web of Science ®Google Scholar
• Veith R C, Featherstone J A, Linares O A, Halter J B. Age difference in plasma norepinephrine kinetics in humans. J Gerontol 1986; 41: 319–324
   PubMedGoogle Scholar
• Takimoto G S, Weiner N. Effect of nitroprusside-induced hypotension on sympathetic nerve activity, tyrosine hydroxylase activity and [3H]norepinephrine uptake in rabbit vascular tissues. J Pharmacol Exp Ther 1981; 219: 420–427
   PubMed Web of Science ®Google Scholar
• Miller R R, Vismara L A, Williams D O, Amsterdam E A, Mason D T. Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure: Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation. Circ Res 1976; 39: 127–133
   PubMed Web of Science ®Google Scholar
• Sowers J R, Mohanty P K. Effect of advancing age on cardiopulmonary baroreceptor function in hypertensive men. Hypertension 1987; 10: 274–279
   PubMed Web of Science ®Google Scholar
• Kezdi P. Baroreceptors in normotension. Progress in brain research. Vol. 47 Hypertension and brain mechanisms, W de Jong, A P Provoost, A P Shapiro. Elsevier, Amsterdam 1977; 35–42
   Google Scholar
• Mento P F, Wilkes B M. Plasma angiotensin and blood pressure during converting enzyme inhibition. Hypertension 1987; 9: III-42–III-48
   Web of Science ®Google Scholar
• Phillips M I, Kimura B. Converting enzyme inhibitors and brain angiotensin. J Caridovasc Pharmacol 1986; 8: S82–S90
   Web of Science ®Google Scholar
• Dluhy R G, Smith K, Taylor T, Hollenberg N K, Williams G H. Prolonged Converting enzyme inhibition in non-modulating hypertension. Hypertension 1989; 13: 371–377
   PubMed Web of Science ®Google Scholar
• Unger T, Badoer E, Ganten D, Lang R E, Retting R. Brain angiotensin: pathways and pharmacology. Circulation 1988; 77: I-40–I-54
   Web of Science ®Google Scholar
• Dzau V J. Significance of the vascular renin-angiotensin pathway. Hypertension 1986; 10: 553–559
   Google Scholar
• Campanole-Santos M J, Diz D I, Ferrario C M. Baroreceptor reflex modulation by angiotensin II at the nucleus tractus solitarii. Hypertension 1988; 11: I-167–I-171
   Web of Science ®Google Scholar
• Okamura T, Miyazaki M, Inagami T, Toda N. Vascualr renin-angiotensin system in two-kidney, one clip hypertensive rats. Hypertension 1986; 8: 560–565
   PubMed Web of Science ®Google Scholar
• Cohen M L, Kurz K D. Angiotensin converting enzyme inhibition in tissues from spontaneously hypertensive rats after treatment with captopril or MK-421. J Pharmacol Exp Ther 1981; 220: 63–69
   Web of Science ®Google Scholar
• Bouthier J D, Safar M E, Benetos A, Simon A C, Levenson J A, Huges C M. Haemodynamic effects of vasodilating drugs on the common carotid and brachial circulations of patients with essential hypertension. Br J Clin Pharmacol 1986; 21: 137–142
   PubMed Web of Science ®Google Scholar
• Zimmermann B G. Actions of angiotensin on adrenergic nerve endings. Fed Proc 1978; 37: 199–202
   PubMedGoogle Scholar
• Erdos E G, Skidgel R A. The unusual substrate specificity and the distribution of human angiotensin I converting enzyme. Hypertension 1986; 8: I-34–I-37
   Web of Science ®Google Scholar
• Floras J S, Aylward P E, Abboud F M, Mark A L. Inhibition of muscle sympathetic nerve activity in humans by arginine vasopressin. Hypertension 1987; 10: 409–416
   PubMed Web of Science ®Google Scholar
• Thibonnier M, Soto M E, Menard J, Aldiger J C, Corvol P, Milliez P. Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. Eur J Clin Invest 1981; 11: 449–453
   PubMed Web of Science ®Google Scholar
• Biollaz J, Brunner H R, Gavras I, Waebar B, Gavras H. Antihypertensive therapy with MK 421: Angiotensin II - renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4: 966–972
   PubMed Web of Science ®Google Scholar